Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
Status:
Not yet recruiting
Trial end date:
2026-04-10
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single-arm study to investigate the safety, tolerability,
PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected
advanced malignancies. Part 1 (dose escalation) will determine the recommended dose of INCA
32459 for expansion (RDE) and the maximum tolerated dose (MTD). Part 2 (dose expansion) will
further evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor
activity of INCA 32459 at the recommended dose(s) for expansion in 2 tumor-specific cohorts.